-
FDA Approves First Biosimilar to Treat Multiple Sclerosis
Tue Aug 29 10:20:42 CST 2023
August 24, 2023, The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).
Send Inquiry
English